Swedish CDMO Recipharm is banking on a growing demand for analytical drug development services, planning to reconstruct its Solna, Sweden, facility to house its data-based offerings.
The site is currently designed for drug formulation and manufacture, and Recipharm plans to outfit it with the technology needed to conduct stability testing, assay development and validation studies, the company said.
"This is a very important step for us, as increasing this capacity will enable the company to enhance the high-quality services to our customers," General Manager Maria Lundberg said in a statement. "Our analytical development service is already an integrated and vital part of the pharmaceutical development work, and this investment will enable our business to continue to grow, creating more flexibility and a better service offering."
Recipharm plans to have the facility re-formed and ready for business by May, and the company said it will be compliant with the demands of the FDA, EU and ICH.
Back in May, Recipharm locked down a $113.2 million loan it planned to use for M&A and internal development. Since then, it has expanded its sterile filling capacity in its Monts, France, facility and signed a deal with Astimex Pharma to develop and manufacture a new therapy.
- check out Recipharm's announcement